Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahner, Sven, Woelber, Linn, Mueller, Volkmar, Witzel, Isabell, Prieske, Katharina, Grimm, Donata, Keller-v Amsberg, Gunhild, Trillsch, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593253/
https://www.ncbi.nlm.nih.gov/pubmed/26500886
http://dx.doi.org/10.3389/fonc.2015.00211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593253/
https://www.ncbi.nlm.nih.gov/pubmed/26500886
http://dx.doi.org/10.3389/fonc.2015.00211

Ejemplares similares